U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07453095) titled 'Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy' on Feb. 16.
Brief Summary: This is a Phase 2, multicentre, single arm study that evaluates the efficacy and safety of glofitamab in MCL patients with inadequate response or relapse following CAR T-cell therapy.
Study Start Date: April 15
Study Type: INTERVENTIONAL
Condition:
Mantle Cell Lymphoma
Intervention:
DRUG: Glofitamab
Glofitamab treatment in post CAR-T R/R MCL patients
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Fondazione Italiana Linfomi - ETS
Published by HT Digital Content Services with permission fro...